Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,354 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Standard of Care Clear all
Terminated Phase 3 Interventional Results available

38 Week Extension Study to CAIN457C2303

NCT01093846
View directory record Official record
Conditions
Uveitis
Interventions
AIN457, Placebo AIN457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Jun 10, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

NCT07116174
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Xcell Amnio Matrix, Standard of Care (SOC)
Biological · Drug
Lead sponsor
New Horizon Medical Solutions
Network
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fresno, California • San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Active, not recruiting Phase 4 Interventional

Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study

NCT04496362
View directory record Official record
Conditions
ECMO, Heparin, Respiratory Failure
Interventions
subcutaneous heparin anticoagulation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray, Radiotherapy 70 Gray, Cisplatin 100 mg/m^2
Biological · Radiation · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
68
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 4 Interventional

Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis

NCT06005168
View directory record Official record
Conditions
Surgical Prophylaxis
Interventions
Cefazolin for Injection
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

NCT03596450
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Standard of care
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
121
States / cities
Buena Park, California • Fullerton, California • Garden Grove, California + 104 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jun 10, 2026, 4:43 PM EDT
Active, not recruiting Phase 3 Interventional

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824
View directory record Official record
Conditions
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Interventions
Acasunlimab, Pembrolizumab, Docetaxel
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Vallejo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Recruiting No phase listed Observational

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT06538038
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions
Osimertinib, Osimertinib + Chemotherapy
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
146
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Active, not recruiting Phase 3 Interventional

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717
View directory record Official record
Conditions
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Interventions
Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen
Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 100 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
7
States / cities
Duarte, California • Orange, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

NCT05538689
View directory record Official record
Conditions
Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions
Myfembree Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Evaluating the Advantages of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care After Cardiac Surgery

NCT06970925
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Sucrosomial Iron (SI)
Dietary Supplement
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 10, 2026, 4:43 PM EDT
Recruiting Phase 3 Interventional

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

NCT07195591
View directory record Official record
Conditions
Glioblastoma
Interventions
GammaTile®, External Beam Radiation Therapy, Temozolomide
Device · Radiation · Drug
Lead sponsor
GT Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Scottsdale, Arizona • Neptune City, New Jersey • Valhalla, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci

NCT02241005
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Vancomycin-Resistant Enterococci
Interventions
Theraworx™ bath wipes, Standard bath wipes
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jun 10, 2026, 4:43 PM EDT
Terminated Phase 3 Interventional Results available

Progesterone for the Treatment of Traumatic Brain Injury III

NCT00822900
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Progesterone, Placebo
Drug
Lead sponsor
David Wright
Other
Eligibility
18 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tuscon, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jun 10, 2026, 4:43 PM EDT
Recruiting Phase 2 Interventional

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

NCT06517212
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancers
Interventions
Tirzepatide
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Fluid Capture Efficiency of the Total Capture Drape Versus a Standard Drape for Hysteroscopy

NCT04540952
View directory record Official record
Conditions
Hysteroscopic Surgery
Interventions
Total Capture Drape, Standard Hysteroscopy Drape
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Jun 10, 2026, 4:43 PM EDT
Terminated Not applicable Interventional Results available

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

NCT01275664
View directory record Official record
Conditions
Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Hinsdale, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Jun 10, 2026, 4:43 PM EDT
Completed No phase listed Observational

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

NCT05541328
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

NCT00284817
View directory record Official record
Conditions
Cancer
Interventions
MEDI-522
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Not applicable Interventional Results available

Non-Complex Biliary Stones DSC vs ERC

NCT03421340
View directory record Official record
Conditions
Biliary Stones
Interventions
DSC, ERC
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Stanford, California • Aurora, Colorado • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Jun 10, 2026, 4:43 PM EDT
Not yet recruiting Phase 3 Interventional

Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure

NCT07018297
View directory record Official record
Conditions
Heart Failure, Acute Decompensated Heart Failure
Interventions
Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Comparing iNPWT Dressing and Devices Affect on Bioburden Levels and Skin Condition After Seven Days

NCT05559697
View directory record Official record
Conditions
Skin Reaction to Mechanical, Thermal and Radiation Stimuli, Skin Sensitisation
Interventions
Sponsor incisional negative pressure wound therapy device and dressing, Standard of Care incisional negative pressure wound therapy system
Device
Lead sponsor
DeRoyal Industries, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

NCT02352948
View directory record Official record
Conditions
Non - Small Cell Lung Cancer NSCLC
Interventions
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
33
States / cities
Chandler, Arizona • Anaheim, California • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Jun 10, 2026, 4:43 PM EDT